A deadly and little-understood strain of Ebola is spreading rapidly across central Africa with no protective vaccine in sight, sparking fears of a major worldwide health crisis.
World Health Organisation officials have upgraded the public health risk of the outbreak from ‘high’ to ‘very high’, with the virus now detected in the Democratic Republic of Congo (DRC) and Uganda.
More than 900 suspected cases and 119 deaths have been reported in DRC – including three Red Cross volunteers who are thought to have contracted the virus while managing dead bodies.
All flights to and from Bunia – the eastern DRC city where most cases and deaths have occurred – have been grounded but experts believe the virus may have already spread to other nearby nations, such as South Sudan.
In previous Ebola outbreaks, the virus has killed more than half of those infected – many of whom died due to internal bleeding and organ failure.
Now, experts are warning that there is no vaccine that can protect against the Ebola variant driving the outbreak – which means the virus will almost certainly continue to spread and kill.
A life-saving jab already exists to protect against the most common form of Ebola – the Zaire variant.
However, the current outbreak has been caused by a different strain, called Bundibugyo.

World Health Organisation says the outbreak poses ‘very high’ risk for Congo, but risk of disease spreading globally remains low
Scientists at Oxford University are racing to develop a Bundibugyo vaccine, but warn that it will take two to three months before the jab can be tested on humans, meaning it is unlikely patients in Africa will get the drug within the next six months.
A successful vaccine would likely protect patients from severe illness and death as well as limit the spread of the virus.
However, there is also no guarantee that the experimental jab will be effective.
Experts say that the Bundibugyo isn’t new but it is rare. The variant was first recorded in 2007 and takes its name from the area of western Uganda where it was spotted.
It then arose for a second time in the DRC in 2012. However, both outbreaks were limited in size – with just over 200 combined confirmed and probable cases and around 66 deaths.
The origin of the Bundibugyo variant is unknown but some researchers believe it was passed onto humans via fruit bats.
It is thought to spread through direct contact with the blood or bodily fluids of a person who is sick or has died from the virus, or through contact with contaminated surfaces.
Symptoms remain the same across all Ebola variants, starting with a flu-like fever, headache, muscle pain, vomiting and diarrhoea before progressing to internal bleeding, organ failure and death.
Your browser does not support iframes.
Your browser does not support iframes.
However, patients can carry the virus for up to 21 days before symptoms begin, which is when experts believe they become infectious.
While the WHO escalated its risk assessment for the DRC, it claims risk at the global level remains low.
The UK has announced up to £20million to help contain the outbreak of Ebola in the eastern region of the DRC.
UK health officials have also activated a Returning Workers Scheme – where healthcare workers returning from Ebola outbreak regions are monitored for signs of the disease once back in the UK.
However, experts have warned that the UK is unprepared for the Ebola outbreak, and argue that the population may be at-risk.
Dr Derek Sloan, an expert in infectious diseases at St Andrew’s University, said the recent outbreak shows we must remain ‘vigilant’ and ‘preserve funding’.
‘This outbreak, along with the recent Hantavirus cases on a cruise ship and meningitis infections in the UK shows how important it is that we stay vigilant and use effective public health tools to protect our populations,’ Dr Sloan, also a spokesman for UK-Med and Healthy World, Secure Britain, said.
‘Infectious disease outbreaks such as these in our interconnected world cannot be dismissed as someone else’s problem.
‘These examples show how important it is to maintain this expertise and underline the need to preserve funding for global health and international aid.’
